menu
    • menu
    [{"orgOrder":0,"company":"Biocept Inc","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"186-Re Obisbemeda","moa":"Beta-radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biocept Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocept Inc \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Biocept Inc \/ Plus Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Biocept Inc

    Menu

    Biocept Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocept Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Biocept Inc

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

                            Details : The agreement will employ Biocept’s cerebrospinal fluid assay CNSide1 in Plus Therapeutics’ ReSPECT-LM Phase 1/2a clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM), which is cancer in the membrane...

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 22, 2022

                            Lead Product(s) : 186-Re Obisbemeda

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth